Symptomatic treatment of recurrent dyspeptic symptoms not related to organic gastrointestinal disease, such as: heartburn, gastric acid hyperacidity, epigastric pain.
Composition:
1 tabl powl. contains 150 mg ranitidine.
Action:
A competitive, reversible H receptor antagonist2. It inhibits basic and stimulated gastric acid secretion. As a result of competitive and selective blocking of histamine binding to the H receptor2 leads to a decrease in the intracellular concentration of cAMP, the stimulator of H action+, K+, ATPase, which plays an essential role in the secretion of hydrogen ions by the parietal cells of the stomach. Ranitidine in doses of 150-300 mg inhibits gastric secretion stimulated by histamine, gastrin, acetylcholine, irritation of the vagus nerve, Caffeine and food. Decreased gastric acidity was also observed after administration of ranitidine at doses of 25 mg, 75 mg and 125 mg, 45%, 71% and 84%, respectively, 5 h after drug administration. The bioavailability of ranitidine is about 50% and increases slightly in liver failure. It binds to plasma proteins in about 15%, crosses the blood / brain barrier, blood / placenta and into breast milk. T0,5 It is about 2.5 hours. It is mainly excreted in the urine.
Contraindications:
Hypersensitivity to ranitidine or other ingredients of the preparation. Liver cirrhosis with portal hypertension. Children under 16 years.
Precautions:
Caution should be exercised when ranitidine is co-administered with anticoagulants, and prothrombin time is periodically monitored. Caution in elderly patients (over 65 years) - they are more likely to experience side effects from the nervous system; special attention should be paid to subtle or overt personality changes or possible interactions with other drugs. Carefully use the preparation in patients with renal and hepatic insufficiency, and in patients on dialysis administered after the end of dialysis. It must not be used in patients with a history of acute porphyria or in patients with rare hereditary problems of galactose intolerance, lactase deficiency (Lapp type) or malabsorption of glucose-galactose. In the elderly, patients with chronic lung disease, diabetes or immunocompromised patients there is a greater risk of developing community-acquired pneumonia. Ranitidine is not recommended for patients with acute pancreatitis and during replacement therapy with pancreatic enzymes. Smoking reduces the effectiveness of the preparation. Patients treated concomitantly with NSAIDs and ranitidine should be checked regularly. This applies especially to elderly patients and patients with a history of peptic ulcer disease.
Pregnancy and lactation:
The preparation can be used during pregnancy only if clearly necessary. It is not recommended to use the product during breastfeeding. Ranitidine is excreted in human milk and may inhibit gastric secretion, inhibit drug metabolism and stimulate o.u.n. in a breast-fed newborn.
Side effects:
Uncommon: abdominal pain, diarrhea, constipation, nausea, vomiting. Rarely: hypersensitivity reactions (urticaria, angioneurotic edema, bronchospasm, fever, hypotension, chest pain), transient changes in liver enzymes, increase in blood creatinine (usually small, these symptoms resolved during treatment), rash. Very rare: leukopenia, thrombocytopenia (these changes are usually reversible), agranulocytosis, pancytopenia, sometimes with hypoplasia or aplasia of the bone marrow; anaphylactic shock, reversible confusion, depression and hallucinations (mainly in severely ill and elderly patients); headache (sometimes severe), dizziness and transient involuntary movement disorders, reversible blurred vision, vasculitis, acute pancreatitis, hepatitis (liver parenchyma, biliary or mixed) with or without icterus, usually reversible; erythema multiforme, alopecia, musculoskeletal symptoms such as joint and muscular pain, acute interstitial nephritis, reversible impotence, gynecomastia and galactorrhea.In addition: increased creatinine, granulocytopenia, rash, Stevens-Johnson syndrome, taste disturbances, confusion, restlessness, visual and auditory hallucinations, bradycardia, atrioventricular block, tachycardia, epigastric pain, bloating or flatulence, isolated cases of transient hypergastrinemia , pruritus, lower libido in men, upper respiratory tract infection, runny nose, influenza and flu-like symptoms.
Dosage:
Orally. Adults and adolescents from 16 years: 150 mg (1 tablet), if necessary 300 mg daily. Do not use a dose higher than 300 mg daily. If the symptoms do not subside after 2 weeks of treatment, the diagnosis should be verified.
(C)
